Filana Therapeutics closed at $0.59 on Nov 3, up 5.94%, 42.3% below its highest close since Sep 11. Volume of 362.1K shares was 1.00× its 20-day average (close to normal).
Split-adjusted performance: -31.7% over one month.
Short interest was 5.6M shares at the Oct 15 settlement, down 4.8% from the prior report (12.2% of float, 6.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| FLNAFilana Therapeutics | $0.5943 | +5.94% | — | — | — | — | $28.7M | |
| ACETAdicet Bio | $3.17 | −0.94% | −62.7% | — | — | — | $29.7M | Compare |
| NXTCNextCure | $5.91 | +3.78% | −36.6% | — | — | — | $27.1M | Compare |
| PMNProMIS Neurosciences Inc. Common Shares (ON) | $3.41 | +13.67% | −69.2% | — | — | — | $30.6M | Compare |
| AARDAardvark Therapeutics | $1.23 | +2.50% | −77.5% | — | — | — | $26.9M | Compare |
| RNAZTransCode Therapeutics | $1.57 | −3.68% | −80.0% | — | — | — | $26.6M | Compare |
| CELUCelularity | $0.8171 | +1.82% | −14.3% | −5.3% | 10.1% | — | $26.5M | Compare |
| ABVCABVC BioPharma | $0.9851 | +0.51% | −4.4% | — | — | — | $26.3M | Compare |
| BCTXBriacell Therapeutics | $3.01 | −2.59% | −26.0% | — | — | — | $26.3M | Compare |
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology